// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























959 Abstracts

Reduction of TGFBR2 in osteoblasts by enzalutamide causes drug resistance in prostate cancer bone metastasis

Alexandra Vander Ark - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients

Benoit Blanchet - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

CB-7598

ARV-110: An androgen receptor PROTAC degrader for prostate cancer

Taavi Neklesa - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Ipatasertib impairs tumor growth in androgen sensitive and castrate resistant prostate cancer: Evidence in preclinical models

Remi M. Adelaiye-Ogala - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Epigenetic re-programming sensitizes prostate cancer cells to anti-androgen therapy

Lanbo Xiao - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

The role of POU3F2 in the aggressive behavior of neuroendocrine prostate cancer

Naoko Kobayashi - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Enzalutamide versus abiraterone as a radiosensitizer in hormone-sensitive prostate cancer cells

Maryam Ghashghaei - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Influence of abiraterone therapy on anti-tumor immunity in genetically engineered mouse prostate cancer models

Eri Banno - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

CB-7598

Alternative polyadenylation of androgen receptor variants in castration-resistant prostate cancer

Jamie L. Van Etten - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptorpositive (ER+) metastatic breast cancer (MBC).

Joyce OShaughnessy - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

CB-7598

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

Weimin Li - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

CB-7598

Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC).

Eleni Efstathiou - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).

Emmanuel S. Antonarakis - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).

Praful Kumar Ravi - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Association of serum (SR) and tissue (TX) abiraterone (ABI) levels with intraprostatic steroids and pathologic outcomes in men with high-risk localized prostate cancer (PCa).

Elahe A. Mostaghel - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

CB-7598

Concordance of ETS fusion status of matched metastatic castration-resistant prostate cancer and primary prostate cancer: Data from NCI 9012, a randomized ETS fusion-stratified phase II trial.

Lakshmi Priya Kunju - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

CB-7598

Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Eric Jay Small - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Genomic analysis of circulating tumor DNA (ctDNA) in plasma of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (abi) and enzalutamide (enza).

Arun Azad - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

Daniel Peter Petrylak - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Scott T. Tagawa - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Copyright © 2026. QuantiNova All rights reserved